EGFR and cancer: Glucose metabolism and chemotherapy resistance are inseparable in tumor progression [11]. Reprogramming of glucose metabolism after chemotherapy is a hallmark of cancer progression, especially with respect to an increase in aerobic glycolysis [12]. Transketolase (TKT) is involved in the pentose phosphate pathway and is upregulated in various cancers [13]. TKT regulates NADPH and EGFR pathway to promote liver cancer progression [14]. AKT phosphorylates and activates TKT activity [12], and in turn, the increase of TKT promotes the expression of AKT [12].